Eclipse Regenesis

company

About

Eclipse Regenesis is a development-stage medical device company focused on harnessing the body’s own tissue regeneration capabilities.

  • 1 - 10

Details

Last Funding Type
Grant
Last Funding Money Raised
$1.70M
Industries
Health Care,Medical Device
Founded date
Jan 1, 2017
Number Of Employee
1 - 10
Operating Status
Active

Eclipse Regenesis is a development-stage medical device company focused on harnessing the body’s own tissue regeneration capabilities to treat important diseases. Its flagship product, the Eclipse XL1 System™, utilizes distraction enterogenesis in a treatment designed to mechanically stimulate the body to produce new, fully-functional intestinal to address Short Bowel Syndrome (SBS). With the support of more than 15 years of scientific research and the participation of SBS thought leaders from around the world, the Eclipse Regenesis team is passionate about pioneering a restorative therapy for a disease state that has no cure today. The Eclipse XL1 System is an investigational device and is not currently available commercially in any region.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$1.70M
Eclipse Regenesis has raised a total of $1.70M in funding over 2 rounds. Their latest funding was raised on Aug 26, 2021 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 26, 2021 Grant $1.70M 1 National Institutes of Health Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Eclipse Regenesis is funded by 1 investors. National Institutes of Health are the most recent investors.
Investor Name Lead Investor Funding Round
National Institutes of Health Yes Grant